Literature DB >> 33354640

Brief Report Treatment of infertility and menopause in a patient with multiple sclerosis affecting the pituitary stalk: a case report.

A Aserlind1, A DeCherney1.   

Abstract

BACKGROUND: Multiple Sclerosis (MS) is an immune-mediated inflammatory disease characterized by demyelination of the CNS that affects women in their child-bearing years. There has been no absolute data to suggest infertility in this population; however, women with MS may exhibit decreased fertility due to various etiologies. Furthermore, their transition into menopause presents unique aspects in patient care.
METHODS: We report a case of a 38 year-old female with a diagnosis of MS with subsequent secondary amenorrhea and primary infertility. Multidisciplinary work-up with was consistent with hypothalamic hypogonadism secondary to MS affecting the pituitary stalk. She was treated for infertility in our clinic as well as management of her menopausal symptoms.
RESULTS: The patient conceived triplets after 2 cycles of ovarian stimulation with injectable gonadotropins and intrauterine insemination. She underwent fetal reduction to twins. After completion of childbearing, she was treated for menopausal symptoms with various hormonal therapies and ultimately remained on oral conjugated estrogens with no symptoms.
CONCLUSION: To our knowledge, this is the first report of infertility caused by suspected MS involvement of the pituitary stalk. In this patient population, infertility treatment can be successful with gonadotropins and alleviation of menopausal symptoms can be achieved with hormone replacement.

Entities:  

Year:  2020        PMID: 33354640      PMCID: PMC7751803          DOI: 10.1097/grh.0000000000000036

Source DB:  PubMed          Journal:  Glob Reprod Health        ISSN: 2473-3709


  14 in total

1.  Serum anti-Müllerian hormone levels in reproductive-age women with relapsing-remitting multiple sclerosis.

Authors:  Jan Thöne; Susanne Kollar; Darryl Nousome; Gisa Ellrichmann; Ingo Kleiter; Ralf Gold; Kerstin Hellwig
Journal:  Mult Scler       Date:  2014-08-21       Impact factor: 6.312

Review 2.  Fertility in patients with multiple sclerosis: current knowledge and future perspectives.

Authors:  P Cavalla; V Rovei; S Masera; M Vercellino; M Massobrio; R Mutani; A Revelli
Journal:  Neurol Sci       Date:  2006-09       Impact factor: 3.307

Review 3.  Estriol: emerging clinical benefits.

Authors:  Emad S Ali; Cheyenne Mangold; Alan N Peiris
Journal:  Menopause       Date:  2017-09       Impact factor: 2.953

4.  Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group.

Authors:  C Confavreux; M Hutchinson; M M Hours; P Cortinovis-Tourniaire; T Moreau
Journal:  N Engl J Med       Date:  1998-07-30       Impact factor: 91.245

5.  Estrogen treatment in multiple sclerosis.

Authors:  Stefan M Gold; Rhonda R Voskuhl
Journal:  J Neurol Sci       Date:  2009-06-18       Impact factor: 3.181

Review 6.  Natural history of multiple sclerosis.

Authors:  B G Weinshenker
Journal:  Ann Neurol       Date:  1994       Impact factor: 10.422

Review 7.  Impact of sex hormones on immune function and multiple sclerosis development.

Authors:  María C Ysrraelit; Jorge Correale
Journal:  Immunology       Date:  2018-10-11       Impact factor: 7.397

Review 8.  Multiple sclerosis management and reproductive changes: A guide for general neurologists.

Authors:  Marwa Kaisey; Nancy Sicotte; Barbara Giesser
Journal:  Neurol Clin Pract       Date:  2018-04

9.  Hormone therapy use and physical quality of life in postmenopausal women with multiple sclerosis.

Authors:  Riley Bove; Charles C White; Kathryn C Fitzgerald; Tanuja Chitnis; Lori Chibnik; Alberto Ascherio; Kassandra L Munger
Journal:  Neurology       Date:  2016-09-07       Impact factor: 9.910

10.  Tamoxifen accelerates the repair of demyelinated lesions in the central nervous system.

Authors:  Ginez A Gonzalez; Matthias P Hofer; Yasir A Syed; Ana I Amaral; Jon Rundle; Saifur Rahman; Chao Zhao; Mark R N Kotter
Journal:  Sci Rep       Date:  2016-08-24       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.